Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).
Checked against the public recordLast updated Nov 20, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Quantgene Inc.
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * This study will include subjects that are diagnosed with a malignancy (cohort 1\) and a negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2). * Subjects of both cohorts must: * Be of age ≥ 18 * Provide written consent for study participation * Subject of cohort 1 must: * Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma Subjects of cohort 2 must: • Meet the listed matching criteria Exclusion Criteria: * Subjects of cohort 1 must not: Have been treated for above diagnosed malignancy * Subjects of cohort 2 must not: * Have been diagnosed/treated for a malignancy previously
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Arizona Cancer CenterTucson, Arizona
- Florida Hospital Celebration HealthCelebration, Florida
- Orlando Health UF Health Cancer CenterOrlando, Florida
- Premier Surgical OncologyCenterville, Ohio
- Kettering Medical CenterDayton, Ohio
- University Hospital of GenevaGeneva
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 20, 2018. Always confirm current availability with the study team.